Can Technology Alone Tackle the Issue of Medicine Adherence?

Apr 15, 2015

Though therapeutic treatments are generally trialled, approved and introduced based on the assumption of correct usage, actual patient adherence has been shown across a range of situations to be less than 50%, resulting in undertreated conditions, increased emergency admissions, and reduced public health outcomes. In the following editorial, David Griffin, Senior Consultant at 42 Technology answers the question: can technology alone tackle the issue of medicine adherence? ...

Read More

When Power Failure is Not an Option

Apr 15, 2015

Smartphones and portable medical devices are being increasingly used together, raising the eyebrows of many in the industry. Here, Neil Oliver, Technical Marketing Manager at Accutronics, explores the safe transition of medical equipment into the rapidly-changing mobile space. ...

Read More

A Review of Clinical Trial Challenges in Rare CNS Diseases

Apr 15, 2015

Last year’s ice bucket challenge raised the profile of a rare CNS disease, amyotrophic lateral sclerosis (ALS), a form of motor neuron disease. There is a paucity of treatments for this disease and, like most CNS diseases both common and rare, nothing that alters the exorable progression, which in the case of ALS is likely to prove fatal in three to five years. Susan Mcgoldrick from QCTR provides a review of clinical trial challenges in rare CNS diseases. ...

Read More

SUSAR Consolidation New Procurement Approach in Pharmacovigilance

Apr 15, 2015

In the past three to five years, pharmacovigilance has witnessed a paradigm shift after release of guidelines by the US Food and Drug Administration (USFDA) and European Medicines Agency (EMA) which has changed the way SUSARs have been managed. Pharmaceutical companies outsource SUSARs under the pharmacovigilance services to various suppliers based upon their geographical, product and service capabilities. Ashwini Tripathi, Senior Research Analyst of Voisin Consulting, explains how Suspected Unexpected Serious Adverse Reactions have become a critical element in analysing the risk and benefit associated with a life cycle of medicinal product either in the market or clinical trials. ...

Read More

Remote Diabetes Trial puts Patients at the Heart of Trial

Apr 15, 2015

Type 2 diabetes might just be the most dangerous non-communicable disease in the history of humankind, but putting patients in charge of their own care could help solve the problem. Zuzanna Fimińska, writer for eyeforpharma, discusses diabetes trials targeting the patients’ point. ...

Read More